期刊
STEM CELL REVIEWS AND REPORTS
卷 6, 期 3, 页码 411-424出版社
SPRINGER
DOI: 10.1007/s12015-010-9134-5
关键词
Stem cells; Donor cell leukemia; Teratoma; Non-teratoma tumors; Graft overgrowth
资金
- Russian Federal Agency for Science and Innovation [02.527.11.0007]
- Russian Academy of Sciences
- NordForsk [080250]
- European Community [241558]
- Swedish Research Council
- Swedish Parkinson Foundation
- Swedish Institute
- Grants-in-Aid for Scientific Research [21591837] Funding Source: KAKEN
Unique biological properties of stem cells make them a precious source of cell material for treatment of a number of pathological conditions. Among issues inhibiting transition of stem cell technologies to the clinics, the risk of oncological complications of stem cell-based therapies is the most critical. A massive amount of clinical and experimental data demonstrates that both hematological (including acute and chronic myeloid leukemia) and non-hematological (including teratoma and non-teratoma tumors) malignancies could arise from donor stem cells of different types. A wide spectrum of mechanisms could underlie the development of oncological disease in recipients, including: i) blast transformation of proliferating donor stem cells under persistent action of certain factors in the recipient, thus causing de novo malignancies; ii) contamination of donor cell material with malignant cells; iii) transmission of particular viral subtypes with donor stem cells, combined with immunosuppression therapy effects; iv) uncontrollable proliferation of residual undifferentiated stem cells of various plasticity; and v) karyotypic instability in stem cells following prolonged culturing/expansion in vitro. Potential preventive strategies are diverse and include i) high-throughput cell sorting-based strategies; ii) introduction of suicide genes into the donor stem cell genome; iii) application of apoptosis-inducing epigenetic factors; and some other options.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据